评估多种免疫产品对婴儿需就医呼吸道合胞病毒(RSV)感染的影响
研究开发了一种工具,供公共卫生官员估算不同免疫策略对12月龄以下婴儿RSV相关需就医下呼吸道感染(LRTI)的影响。以美国出生队列为例,未免疫时门诊、急诊和住院LRTI分别为407,360、147,240和33,180例;针对所有婴儿的被动抗体候选产品预防效果最大,可分别减少48%、51%和55%的 visits;母体疫苗候选产品联合帕利珠单抗策略分别减少14%、13%和25%。结论强调预期产品可减少严重RSV疾病,工具可供不同辖区使用并接受更新数据。
要点
- 未免疫时美国出生队列每年门诊、急诊、住院LRTI分别为407,360、147,240、33,180例。
- 针对所有婴儿的被动抗体候选产品预防最多LRTI:门诊196,470例(48%)、急诊75,250例(51%)、住院18,140例(55%)。
- 母体疫苗候选产品联合帕利珠单抗策略预防门诊58,210例(14%)、急诊19,580例(13%)、住院8,190例(25%)。
核心结论
- 结果强调预期产品减少严重RSV疾病的潜力,工具可供不同辖区使用并接受更新数据,结果可辅助经济评价和公共卫生决策。
研究设计与样本
- 开发供公共卫生官员使用的工具,估算免疫策略对12月龄以下婴儿RSV相关需就医LRTI的影响,用户输入RSV负担和季节性并检查产品效力和接种率假设变化的影响,以美国出生队列评估候选产品影响。
主要发现
- 未免疫时,每年门诊就诊407,360例(范围:339,650-475,980)LRTI,急诊147,240例(126,070-168,510),住院33,180例(24,760-42,900)。
- 针对所有婴儿的被动抗体候选产品预防门诊196,470例(占未免疫就诊48%,范围:163,810-229,650)、急诊75,250例(51%,64,430-86,090)、住院18,140例(55%,13,770-23,160)。
- 母体疫苗候选产品联合帕利珠单抗策略预防门诊58,210例(占未免疫就诊14%,范围:48,520-67,970)、急诊19,580例(13%,16,760-22,400)、住院8,190例(25%,6,390-10,150)。
临床怎么用
- 工具(提供给读者)可供不同辖区使用并接受更新数据,结果可辅助经济评价和公共卫生决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palivizumab, a monoclonal antibody and the only licensed immunization product for preventing respiratory syncytial virus (RSV) infection, is recommended for children with certain high-risk conditions. Other antibody products and maternal vaccines targeting young infants are in clinical development. Few studies have compared products closest to potential licensure and have primarily focused on the effects on hospitalizations only. Estimates of the impact of these products on medically-attended (MA) infections in a variety of healthcare settings are needed to assist with developing RSV immunization recommendations. METHODS: We developed a tool for practicing public health officials to estimate the impact of immunization strategies on RSV-associated MA lower respiratory tract infections (LRTIs) in various healthcare settings among infants <12 months. Users input RSV burden and seasonality and examine the influence of altering product efficacy and uptake assumptions. We used the tool to evaluate candidate products' impacts among a US birth cohort. RESULTS: We estimated without immunization, 407,360 (range: 339,650-475,980) LRTIs are attended annually in outpatient clinics, 147,240 (126,070-168,510) in emergency departments (EDs), and 33,180 (24,760-42,900) in hospitals. A passive antibody candidate targeting all infants prevented the most LRTIs: 196,470 (48% of visits without immunization) outpatient clinic visits (range: 163,810-229,650), 75,250 (51%) EDs visits (64,430-86,090), and 18,140 (55%) hospitalizations (13,770-23,160). A strategy combining maternal vaccine candidate and palivizumab prevented 58,210 (14% of visits without immunization) LRTIs in outpatient clinics (range: 48,520-67,970), 19,580 (13%) in EDs (16,760-22,400), and 8,190 (25%) hospitalizations (6,390-10,150). CONCLUSIONS: Results underscore the potential for anticipated products to reduce serious RSV illness. Our tool (provided to readers) can be used by different jurisdictions and accept updated data. Results can aid economic evaluations and public health decision-making regarding RSV immunization products.
引用
- Rainisch G, Adhikari B, Meltzer MI, et al. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine. 2019. PMID: 31740097. doi:10.1016/j.vaccine.2019.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。